Table 3.

Gastrointestinal symptoms due to COVID-19 in adult patients on VDZ compared to those on other IBD therapies, and on VDZ monotherapy compared to anti-TNF monotherapy, in the SECURE-IBD registry, overall and stratified by IBD activity

Gastrointestinal symptom	VDZ use vs non-use					VDZ monotherapy vs anti-TNF monotherapy
	VDZ		All other IBD therapies		p value	Vedolizumab monotherapy		Anti-TNF monotherapy		p value
	N	[%]	N	[%]		N	[%]	N	[%]
Overall
Abdominal pain	37	8.1%	250	7.8%	0.847	30	9.0%	58	5.6%	0.026
Diarrhoea	89	19.5%	616	19.3%	0.934	74	22.2%	167	16.0%	0.010
Nausea	32	7.0%	167	5.2%	0.120	29	8.7%	38	3.6%	<0.001
Vomiting	14	3.1%	86	2.7%	0.653	12	3.6%	18	1.7%	0.042
Other	10	2.2%	88	2.8%	0.481	9	2.7%	19	1.8%	0.325
Any GI symptom	116	25.4%	770	24.1%	0.822	99	29.6%	200	19.2%	<0.001
Among patients with active IBD a
Abdominal pain	18	8.7%	148	11.3%	0.258	13	10.0%	35	10.6%	0.840
Diarrhoea	41	19.8%	289	22.1%	0.449	30	23.1%	80	24.3%	0.779
Nausea	12	5.8%	84	6.4%	0.726	10	7.7%	15	4.6%	0.183
Vomiting	6	2.9%	43	3.3%	0.765	5	3.8%	8	2.4%	0.532
Other	4	1.9%	41	3.1%	0.341	3	2.3%	11	3.3%	0.766
Any GI symptom	49	23.7%	353	27.0%	0.556	37	28.5%	95	28.9%	0.875
Among patients with IBD in remission a
Abdominal pain	18	7.9%	93	5.3%	0.109	17	9.0%	23	3.4%	0.001
Diarrhoea	46	20.2%	292	16.6%	0.183	43	22.9%	82	12.3%	<0.001
Nausea	20	8.8%	77	4.4%	0.004	19	10.1%	23	3.4%	<0.001
Vomiting	8	3.5%	38	2.2%	0.205	7	3.7%	10	1.5%	0.072
Other	5	2.2%	39	2.2%	0.977	5	2.7%	7	1.0%	0.150
Any GI symptom	64	28.1%	374	21.3%	0.027	60	31.9%	99	14.8%	<0.001

Abbreviations: COVID-19 = coronavirus disease 2019; SECURE-IBD = Surveillance Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease; VDZ = vedolizumab; TNF = tumor necrosis factor.

Statistically significant associations are in bold.

^aBased on Physician Global Assessment [PGA].